Apogenix GmbH said that a final analysis of data from its Phase 2 proof-of-concept trial of a new drug for glioblastoma, APG101, confirmed the agent’s therapeutic effect as well as its safety and tolerability. The trial recruited 84 patients in 25 centres in Europe.
